Search clinical trials for: IBI346/

Total 345 results

Harbin Medical University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Advanced Cervical Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

Acral Melanoma That Has Been Removed by Surgery

China
The First Affiliated Hospital of Soochow University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#

Relapsed/Refractory Multiple Myeloma

China
Chunrui Li
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#

Relapsed/Refractory Multiple Myeloma

China
Shenzhen People's Hospital

Recruiting

Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia

Lipid Metabolism Disorders | Familial Hypercholesterolemia - Homozygous | Proprotein Convertase Subtilisin/Kexin 9

China
Tongji Hospital
Wuhan University; Henan Cancer Hospital; Qilu Hospital of Shandong University; Hubei... and other collaborators

Recruiting

Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (INOVA)

Ovarian Clear Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345

CLDN18.2 Positive Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI306 in HeFH Patients

Heterozygous Familial Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Indolent Non-hodgkin Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

Healthy Participants | Atopic Dermatitis Patients

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI306 in Participants With Hypercholesterolemia

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers

Healthy Male Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19

COVID-19

China
Hunan Province Tumor Hospital
Xiangya Hospital of Central South University

Recruiting

The Efficacy and Safety of IBI363 in Solid Tumors (Promise)

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Clinical Study of IBI362 in Healthy Chinese Male Subjects

Overweight/Obesity

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

Overweight or Obesity

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

NPC

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Peking University
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

Thyroid Eye Disease, TED

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI363 in Subjects With Advanced Melanoma

Melanoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Study of IBI323 in Patients With Advanced Malignancies

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

Renal Impairment

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study of IBI318 in Participants With Advanced Malignancies

Advanced Malignancy

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Study of IBI363 in Subjects With Advanced Solid Malignancies

Solid Tumors

United States
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Advanced Cutaneous Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

Advanced/Metastatic Solid Malignancies

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI353 (Orismilast) in Chinese Healthy Adults

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Safety and Tolerability of IBI355 in Healthy Volunteers

Healthy

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI362 9 mg in Chinese Adults With Obesity

Obesity

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Safety and Tolerance Study of IBI355 in Health Volunteers

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Overweight/ Obesity

China

Search clinical trials for: IBI346/

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations